Table 3.
Effects of AEDs, SNPs and vitamins on Hcy levels in patients with epilepsy.
Model | Unstandardized coefficients | Standardized coefficients | P-value | VIF | R2 | |
---|---|---|---|---|---|---|
β | Std. error | Beta | ||||
(Constant) | 17.645 | 1.465 | <0.001 | 0.28 | ||
FA (nmol/l) | −0.192 | 0.032 | −0.33 | <0.001 | 1.125 | |
vit B12 (pmol/l) | −0.008 | 0.002 | −0.205 | <0.001 | 1.156 | |
VPA | 2.406 | 1.048 | 0.151 | 0.023 | 1.587 | |
OXC | 1.968 | 0.957 | 0.137 | 0.041 | 1.628 | |
LTG | 0.435 | 1.011 | 0.028 | 0.668 | 1.519 | |
LEV | 1.421 | 1.157 | 0.075 | 0.22 | 1.379 | |
rs1801133 CT | −0.182 | 0.719 | −0.014 | 0.801 | 1.141 | |
rs1801133 TT | 6.334 | 1.424 | 0.242 | <0.001 | 1.09 | |
rs1801198 CC | 1.91 | 0.92 | 0.119 | 0.039 | 1.204 | |
rs1801198 GG | 0.716 | 0.745 | 0.054 | 0.337 | 1.168 | |
rs2071010 AA | 4.464 | 2.063 | 0.119 | 0.031 | 1.113 | |
rs2071010 GG | 1.207 | 0.727 | 0.09 | 0.098 | 1.089 |
The overall significance for Hcy levels was F = 8.583; P < 0.001. P < 0.05 was considered a statistically significant difference.
FA, folate; vit B12, vitamin B12; VPA, valproate; OXC, oxcarbazepine; LTG, lamotrigine; LEV, levetiracetam; VIF, variable inflation factor.